Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 6/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885891 | 0.80 | METAP2 (0.40) | METAP2RENKCNA5TACR1NAAA | |
| SCHEMBL6886738 | 0.79 | METAP2 (0.47) | METAP2ALDH1A1 | |
| SCHEMBL6549228 | 0.75 | PSEN1 (0.37) | RENKCNA5TACR1ALDH1A1 | |
| SCHEMBL6885649 | 0.75 | PSEN1 (0.37) | RENKCNA5TACR1ALDH1A1 | |
| SCHEMBL9209896 | 0.70 | METAP2 (0.63) | METAP2ALDH1A1 | |
| SCHEMBL6878395 | 0.69 | METAP2 (0.46) | METAP2RENTACR1 | |
| SCHEMBL6548680 | 0.64 | REN (0.40) | RENKCNA5TACR1NAAA | |
| SCHEMBL18615761 | 0.63 | NAAA (0.54) | RENKCNA5NAAA | |
| SCHEMBL22588318 | 0.61 | REN (0.44) | RENKCNA5TACR1NAAA | |
| SCHEMBL22454181 | 0.61 | NAAA (0.56) | KCNA5NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803382-B2 | 1-OXASPIRO(2,5)OCTAN-6-OL DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-10-12 | — | — | US | disclosed |
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | VEGFA, KDR, FLT1 | METAP2 2357/4885REN 2405/4885KCNA5 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.